Response: Commentary: The Impact of the Time Interval Between Radiation and Hyperthermia on Clinical Outcome in Patients With Locally Advanced Cervical Cancer-Reference-Cited by-同舟云学术

Response: Commentary: The Impact of the Time Interval Between Radiation and Hyperthermia on Clinical Outcome in Patients With Locally Advanced Cervical Cancer

Published:2020-04-15 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Crezee Johannes,Oei Arlene L.,Franken Nicolaas A. P.,Stalpers Lukas J. A.,Kok H. Petra

Funder

KWF Kankerbestrijding

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference28 articles.

1. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer;Oei;Adv Drug Deliv Rev,2020

2. Response of cells to hyperthermia under acute and chronic hypoxic conditions;Gerweck;Cancer Res.,1979

3. Relationship of changes in pH and energy status to hypoxic cell fraction and hyperthermia sensitivity;Koutcher;Int J Rad Oncol Biol Phys.,1990

4. Quercetin sensitizes cells in a tumour-like low pH environment to hyperthermia;Wachsberger;Int J Hyperthermia.,2003

5. Blood flow and associated pathophysiology of uterine cervix cancers: characterisation and relevance for localised hyperthermia;Vaupel;Int J Hyperthermia.,2012

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of the Effect of Hyperthermia in the Treatment of Various Types of Cancer;Clinical Cancer Investigation Journal;2024

2. Radiosensitization by Hyperthermia Critically Depends on the Time Interval;International Journal of Radiation Oncology*Biology*Physics;2023-10

3. The Relevance of High Temperatures and Short Time Intervals Between Radiation Therapy and Hyperthermia: Insights in Terms of Predicted Equivalent Enhanced Radiation Dose;International Journal of Radiation Oncology*Biology*Physics;2023-03

4. Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1-Mutated Cancer Cells;Cancers;2022-12-17

5. Biological modeling in thermoradiotherapy: present status and ongoing developments toward routine clinical use;International Journal of Hyperthermia;2022-08-23